Search results
Showing 631 to 645 of 1455 results for do not do recommendations
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis in adults
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.
Join NICE's people and communities network
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
Recommendation ID NG183/1 Question How can providers and healthcare professionals identify groups that do not initially...
Recommendation ID PH35/4 Question How do socioeconomic, environmental, biological and psychosocial factors determine diet...
Recommendation ID NG224/04 Question Symptoms and signs of long-term (chronic) UTI: What symptoms and signs do children and...
Recommendation ID PH44/7 Question Are the Department of Health's 'Let's get moving' physical activity care pathway and the general...
Digital technologies for managing non-specific low back pain: early value assessment (HTE16)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over....
View recommendations for HTE16Show all sections
This guideline covers organising and delivering end of life care services, which provide care and support in the final weeks and months of life (or for some conditions, years), and the planning and preparation for this. It aims to ensure that people have access to the care that they want and need in all care settings. It also includes advice on services for carers.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Recommendation ID PH41/2 Question What key factors influence the effectiveness of population-level or whole-area approaches to...